The Vivace Therapeutics pan-TEAD transcription factor inhibitor, VT-104, binds to a lipid pocket on TEAD, preventing its auto-palmitoylation, similar to a previously highlighted TEAD inhibitor. In contrast to previously published TEAD inhibitors, VT104 has high oral bioavailability (78%) and a long half-life (24 h) in mice, and demonstrates [...]